Business
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"text","content":"FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that data for vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders, will be presented at the ACG 2021 Annual Scientific Meeting in Las Vegas, Nevada, organized by the American College of Gastroenterology, October 22-27. During the scientific congress, new data on vonoprazan will be shared in addition to novel insights into the burden of acid-related diseases, analysis of treatment patterns, and other newfound developments. “Phathom is committed to its mission as we seek to change the landscape for acid-related diseases,” said Eckhard Leifke, M.D., Chief Medical Officer of Phathom. “We’ve conducted extensive research specifically on H. pylori and erosive esophagitis and look forward to sharing our data as well as updates on the disease burden for patients and providers with the GI community at the ACG 2021 Annual Scientific Meeting.” In addition to four poster sessions and one oral presentation, Phathom will sponsor a product theater highlighting unmet needs in the treatment of H. pylori and will also have a presence on the exhibit floor at booth #929 throughout the conference and virtually via RethinkGIAcid.com. A high-level schedule of Phathom activities at the ACG 2021 Annual Scientific Meeting can be found below: Sunday, October 24, 2021 Phathom Poster Session3:30 PM – 7:00 PMPhathom Poster Session3:30 PM – 7:00 PM Monday, October 25, 2021 Phathom Poster Session10:30 AM – 4:15 PMPhathom Oral Session2:15 PM – 2:25 PM Tuesday, October 26, 2021 Medscape CME symposium sponsored by Phathom6:00 AM – 7:00 AMPresenters: Drs. William D. Chey, Colin Howden, Shailja ShahPhathom Poster Session10:30 AM – 4:15 PMProduct Theater sponsored by Phathom10:35 AM – 11:30 AM Phathom will attend ACG 2021 having recently announced positive data from its pivotal Phase 3 PHALCON-EE trial which studied vonoprazan as a treatment option for erosive esophagitis (EE). Two New Drug Applications (NDAs) for vonoprazan-based regimens for the treatment of H. pylori infection were submitted to the U.S. FDA ...